— Know what they know.
Not Investment Advice

EMCURE.NS

Emcure Pharmaceuticals Ltd.
1W: +5.5% 1M: +10.8% 3M: +19.0% YTD: +5.3% 1Y: +27.8%
₹1,633.20 ($17.35)
+39.80 (+2.50%)
 
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ₹302.1B · Alpha Radar Strong Buy · Power 66
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap₹302.1B ($3.2B)
52W Range889-1621.7
Volume524,419
Avg Volume236,779
Beta0.97
Dividend₹3.00
Analyst Ratings
No analyst coverage
Company Info
CEOSatish Ramanlal Mehta
Employees6,731
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2024-07-10
Websiteemcure.com
Plot No. P-1 and P-2
Pune 411057
IN
91 20 3507 0033
About Emcure Pharmaceuticals Ltd.

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms